CN1895249A - Compound preparation for treating hypentension - Google Patents
Compound preparation for treating hypentension Download PDFInfo
- Publication number
- CN1895249A CN1895249A CN 200510041038 CN200510041038A CN1895249A CN 1895249 A CN1895249 A CN 1895249A CN 200510041038 CN200510041038 CN 200510041038 CN 200510041038 A CN200510041038 A CN 200510041038A CN 1895249 A CN1895249 A CN 1895249A
- Authority
- CN
- China
- Prior art keywords
- preparation
- atenolol
- nitrendipine
- compound antihypertensive
- antihypertensive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
An anti-hypertensive medicine in the form of tablet, capsule, particle, or their slow-release products contains nitrendipine and atenolol in the ratio of 1:2.
Description
Invention field;
The present invention relates to field of pharmaceutical preparations, disclose a kind of compound antihypertensive preparation.
Background technology:
The nitrendipine chemistry is by name: 2, and 6-dimethyl-4-(3-nitrobenzophenone)-1,4-dihydro-3,5-pyridinedicarboxylic acid methyl ethyl ester.
Structural formula is as follows:
The atenolol chemistry is by name: the amino-2-hydroxyl 4-[3-[(1-Methylethyl)] propoxyl group] phenyl acetamide
Structural formula is as follows:
Nitrendipine is a kind of bihydropyridine type calcium antagonist, this product blood vessel selectivity height, expansible coronary artery and peripheral blood vessel, rapid-action, safety, gentleness, lasting; The less water-sodium retention that occurs can reduce myocardial oxygen consumption, and ischemic myocardium is had protective effect; When heavy dose of no postural hypotension the reflexive increased heart rate can appear; Take curative effect for a long time and do not subtract, no cumulative action.
Atenolol then belongs to selectivity β
1-receptor blocking agent, no intrinsic sympathomimetic acitivity, no quinidine sample cardiac muscle inhibitory action is not passed through blood brain barrier; Be used for the treatment of hypertension, angina pectoris and arrhythmia.
Goal of the invention
Product of the present invention has overcome when using nitrendipine and atenolol clinically now, is to guarantee that curative effect increases drug dose during singly with a medicine, causes side effect obviously to increase; During drug combination,, and use clinical medicine dose inaccurate, influence the defective of curative effect of medication because of nothing meets the pharmaceutical preparation of drug combination dosage.Nitrendipine and atenolol two medicines share, and collaborative, complementary action that curative effect has has been strengthened target organ protection function; Reduce consumption, alleviate untoward reaction, taking convenience, cheap.
Summary of the invention
China has 100,000,000 hypertensive patients at present approximately.The Epidemiological study result showed in 1991, and China city and rural area hypertension awareness are respectively 36% and 13%, and treatment rate is respectively 17% and 5%, and control rate is respectively 4% and 0.9%, and the situation of hypertension prevention and control is quite severe.Yet, hypertension therapeutic is a secular process, medical expense (mainly being the price of antihypertensive drug) is the tender subject that government, drug development and production division, hospital and common people pay special attention to, and also is one of factor of restriction China's hypertension therapeutic rate and control rate raising.Especially current, improve the ratio of the benefit/price of antihypertensive drug, to advancing Health Insurance System Reform of crucial importance.
Compound antihypertensive preparation is invented under above-mentioned background.This medicine is the compound tablet that nitrendipine and atenolol are formed, and every contains nitrendipine 5mg and atenolol 10mg.Wherein nitrendipine is a kind of bihydropyridine type calcium antagonist, blood vessel selectivity height, expansible coronary artery and peripheral blood vessel, rapid-action, safety, gentleness, lasting; Simultaneously, also can reduce water-sodium retention, reduce myocardial oxygen consumption, the protective effect of ischemic myocardium tool.Atenolol then is a kind of selectivity β
1-receptor blocking agent, no intrinsic sympathomimetic acitivity, no quinidine sample cardiac muscle inhibitory action is not passed through blood brain barrier.Two medicines share, and curative effect is collaborative, complementary, strengthen target organ protection function; Reduce consumption, alleviate untoward reaction, taking convenience, cheap.
Compound antihypertensive preparation of the present invention, get nitrendipine, atenolol and suitable adjuvant and mix the back granulation, tabletting, promptly, each compound antihypertensive preparation unit contains nitrendipine 5mg, atenolol 10mg, and its content is limited to the 90-110% of each standard content.Preparation can be various preparations, as: solid preparation and their controlled release and slow releasing preparation such as tablet, capsule, granule.
Claims (5)
1, a kind of compound antihypertensive preparation is characterized in that by calcium antagonist--nitrendipine and beta-blocker--compound antihypertensive drug that atenolol is formed.
2, the described compound antihypertensive preparation of claim 1 contains nitrendipine 2-50mg and atenolol 5-100mg in its each compound antihypertensive preparation unit.
3, the described compound antihypertensive preparation of claim, its best proportioning is a nitrendipine: atenolol (1: 2) promptly contains nitrendipine 5mg and atenolol 10mg in each compound antihypertensive preparation.
4, claim 1,2 described compound antihypertensive preparations, wherein each compound antihypertensive preparation unit contains nitrendipine and atenolol, and its content is limited to the 90-110% of each standard content.
5, the described compound antihypertensive preparation of claim 4, wherein preparation can be various preparations, as: solid preparation and their controlled release and slow releasing preparation such as tablet, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041038 CN1895249A (en) | 2005-07-15 | 2005-07-15 | Compound preparation for treating hypentension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510041038 CN1895249A (en) | 2005-07-15 | 2005-07-15 | Compound preparation for treating hypentension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1895249A true CN1895249A (en) | 2007-01-17 |
Family
ID=37607986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510041038 Pending CN1895249A (en) | 2005-07-15 | 2005-07-15 | Compound preparation for treating hypentension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1895249A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239723A (en) * | 2013-04-26 | 2013-08-14 | 江苏吉贝尔药业有限公司 | Compound antihypertensive agent |
-
2005
- 2005-07-15 CN CN 200510041038 patent/CN1895249A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239723A (en) * | 2013-04-26 | 2013-08-14 | 江苏吉贝尔药业有限公司 | Compound antihypertensive agent |
| CN103239723B (en) * | 2013-04-26 | 2014-03-19 | 江苏吉贝尔药业有限公司 | Compound antihypertensive agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101370486A (en) | Transdermal patch containing Isosorbide Dinitrate and bisoprolol | |
| CN102008485A (en) | Losartan-containing compound preparation for treating hypertension | |
| US20070237815A1 (en) | Dosage forms and methods comprising amlodipine and chlorthalidone | |
| JPH02290823A (en) | Synergistic composition containing ketanserin | |
| CN102008712A (en) | Trandolapril-containing compound preparation for curing hypertension | |
| JP2002535367A5 (en) | ||
| CN1895249A (en) | Compound preparation for treating hypentension | |
| CN101229372B (en) | Medicine compounds for treating hypertension | |
| CN101292962B (en) | Felodipine controlled release formulation and preparation method thereof | |
| CN101766611B (en) | Medical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta-blocker and application thereof | |
| CN100496606C (en) | Composite preparation containing nitrate esters medicine and HMG-CoA reductase inhibitor | |
| WO1997006800A1 (en) | Remedy for anxiety neurosis | |
| CN101785781B (en) | Medicine combination of levoamlodipine or medicinal salt of levoamlodipine and auricularia auricula polysaccharide, and application thereof | |
| CN103800307A (en) | Medicinal composition for reducing blood pressure and preparation method thereof | |
| CN110755429A (en) | Compound antihypertensive medicine composition, preparation and application thereof | |
| CN112870213B (en) | Pharmaceutical composition for treating hypertension, solid oral preparation and application thereof | |
| CN101756968A (en) | Novel compound antihypertensive drug | |
| CN101843892B (en) | Medicament composition comprising Enalapril quick-releasing part and felodipine slow-releasing part | |
| CN101559057A (en) | Drug compound for curing hyperlipoidemia and preparation method thereof | |
| CN101229156B (en) | Medicine composition used for cardiovascular disorders | |
| Isles et al. | A randomised double-blind study comparing nifedipine GITS 20 mg and bendrofluazide 2.5 mg administered once daily in mild-to-moderate hypertension | |
| CN101904845A (en) | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs | |
| CN104758285A (en) | Novel compound anti-hypertensive drug | |
| CN101904847A (en) | Amlodipine nicotinate with synergetic pressure reducing function and treatment composition thereof with statin drugs | |
| CN102430109A (en) | Amlodipine, aliskiren and pril compound antihypertensive medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |